The Consensus Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes have identified a number of agents as either first- or later-line. Partially in response to this Consensus Statement, the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) convened a consensus panel and issued their statement on glycemic control in T2DM. In developing their treatment algorithm, they set as priorities minimizing the risk and severity of hypoglycemia and minimizing the risk and magnitude of weight gain. Consequently, the AACE/ACE Diabetes algorithm for glycemic control features a more prominent role for certain agents given their impact on weight and their relative risk of hypoglycemia. The relatively recent nature of these guidelines updates implicitly suggests a practice gap that may be remedied by raising awareness through continuing education learning activities.
Ratings and Reviews
To review this course, please login.Login